Biologics for eosinophilic oesophagitis: a systematic review and meta-analysis DOI Creative Commons
Beibei Zeng,

Dao‐Yong Jia,

Shengen Li

et al.

Annals of Medicine, Journal Year: 2024, Volume and Issue: 57(1)

Published: Dec. 21, 2024

Objective Advancing the understanding of pathophysiology eosinophilic oesophagitis (EoE) and other gastrointestinal diseases (EGIDs) has spurred research into targeted biological therapies, while conclusive therapeutic efficacy biologics remains uncertain. In this review, we conducted a meta-analysis all RCTS in treatment EoE to evaluate their safety discussed non-EoE EGIDs.

Language: Английский

The Dynamic Evolution of Eosinophilic Esophagitis DOI Creative Commons

Amir Farah,

Tarek Assaf,

Jawad Hindy

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(3), P. 240 - 240

Published: Jan. 21, 2025

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus characterized by eosinophilic infiltration, and hallmark symptoms esophageal dysfunction such as dysphagia food impaction. Over past three decades, EoE has been recognized distinct clinical entity, distinguished from gastroesophageal reflux disease (GERD) through advancements in diagnostic techniques, particularly endoscopy with biopsy. The rising global prevalence reflects enhanced awareness, evolving criteria, environmental along lifestyle changes. etiology multifactorial, involving genetic predispositions, immune dysregulation, gut microbiome, triggers, including dietary allergens aeroallergens. Key mechanisms include type 2 helper T-cell (Th2)-driven response, epithelial barrier dysfunction, variants CAPN14 TSLP. Chronic inflammation leads to tissue remodeling, fibrosis, narrowing, contributing progression complications. Management strategies have evolved elimination, proton pump inhibitors, topical corticosteroids, biologics, endoscopic interventions for fibrostenotic Emerging therapies targeting cytokines interleukin (IL)-4, IL-5, IL-13, alongside novel tools like string test Cytosponge, offer promising avenues improved control non-invasive monitoring. Long-term surveillance combining histological evaluations biomarkers critical optimizing outcomes preventing Future research should address gaps understanding role refine therapeutic approaches, develop personalized improve management patient quality life.

Language: Английский

Citations

0

Systemic barrier dysfunction in type 2 inflammation diseases: perspective in the skin, airways, and gastrointestinal tract DOI Creative Commons
Juan Meng, Hao Xiao, Feng Xu

et al.

Immunologic Research, Journal Year: 2025, Volume and Issue: 73(1)

Published: March 11, 2025

The epithelial barrier in different organs is the first line of defense against environmental insults and allergens, with type 2 immunity serving as a protective function. Genetic factors, biological chemical from surrounding environment altered regulate homeostasis through disruption tight junction proteins or dilated intercellular spaces. Recent studies suggest that dysfunction contributes to pathologic alteration diseases immune dysregulation including (but not limited to) atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis nasal polyps, eosinophilic esophagitis. In this review, we summarized current understanding its interaction inflammation across organs, discussed role pathogenesis inflammation. addition, recent progresses emerging restorative therapies are reviewed.

Language: Английский

Citations

0

Eosinophilic Jejunitis Presenting as Intractable Vomiting, Persistent Leukocytosis, and Ascites in a Young Adult Patient DOI Open Access

Dawood Tahir,

Shravya Ginnaram,

Erkanda Ikonomi

et al.

Journal of Medical Cases, Journal Year: 2024, Volume and Issue: 15(6), P. 102 - 105

Published: May 25, 2024

Eosinophilic enteritis (EoN) poses a distinctive challenge, affecting individuals with various clinical presentations depending on the layer and extent of bowel wall. We present case 19-year-old female abdominal pain, vomiting, loose stools for 1 month. Labs were significant persistent leukocytosis peripheral eosinophilia. A computed tomography abdomen/pelvis demonstrated moderate ascites moderately diffuse mucosal thickening jejunal loops. diagnostic paracentesis unveiled low serum albumin gradient 92% eosinophils. Push enteroscopy resulted in no biopsy findings, though laparoscopic full-thickness exhibited increased eosinophils Intravenous steroid, proton pump inhibitor, dietary changes resolved symptoms normalized labs within week. Our report highlights variable presentation eosinophilic jejunitis uncommon this disease population. EoN is an easily missed diagnosis mandates frequent follow-up to prompt relevant investigations. Atopic features are not prevalent each case. While rare, requires strong suspicion, even if endoscopic biopsies unremarkable, prompting timely biopsy. Per protocol, physicians must do infectious eosinophilia workup rule out other etiologies. also that worsening condition warrants early intravenous steroids favorable prognosis considers psychosocial aspect patient's health.

Language: Английский

Citations

1

Eosinophilic esophagitis DOI Creative Commons
Stephanie C. Erdle,

Stuart Carr,

Edmond S. Chan

et al.

Allergy Asthma and Clinical Immunology, Journal Year: 2024, Volume and Issue: 20(S3)

Published: Dec. 19, 2024

Abstract Eosinophilic esophagitis (EoE) is an atopic condition of the esophagus that has become increasingly recognized. Diagnosis disorder dependent on patient’s clinical manifestations and must be confirmed by histologic findings esophageal mucosal biopsies. The epidemiology, pathophysiology, diagnosis, treatment, prognosis EoE are discussed in this review.

Language: Английский

Citations

1

Biologics for eosinophilic oesophagitis: a systematic review and meta-analysis DOI Creative Commons
Beibei Zeng,

Dao‐Yong Jia,

Shengen Li

et al.

Annals of Medicine, Journal Year: 2024, Volume and Issue: 57(1)

Published: Dec. 21, 2024

Objective Advancing the understanding of pathophysiology eosinophilic oesophagitis (EoE) and other gastrointestinal diseases (EGIDs) has spurred research into targeted biological therapies, while conclusive therapeutic efficacy biologics remains uncertain. In this review, we conducted a meta-analysis all RCTS in treatment EoE to evaluate their safety discussed non-EoE EGIDs.

Language: Английский

Citations

1